The effects of dose staggering on metabolic drug-drug interactions

European Journal of Pharmaceutical Sciences

Volumn 20, Issue 2, 2003, Pages 223-232

  Yang, Jiansong ^a   Kjellsson, Maria ^a,b   Rostami Hodjegan, Amin ^a,c   Tucker, Geoffrey T ^a  

^a UNIVERSITY OF SHEFFIELD   (United Kingdom)

^b UPPSALA UNIVERSITY   (Sweden)

^c ROYAL HALLAMSHIRE HOSPITAL   (United Kingdom)

Author keywords

Dose staggering; Drug drug interactions; Enzyme inhibition; Itraconazole; Ketoconazole; Simulation

Indexed keywords

ERROR ANALYSIS; PHARMACOKINETICS; PHYSIOLOGY;

DOSE STAGGERING;

DRUG PRODUCTS;

BUDESONIDE; ITRACONAZOLE; KETOCONAZOLE; LIVER EXTRACT; TRIAZOLAM;

AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; DRUG ELIMINATION; HALF LIFE TIME; HUMAN; HUMAN EXPERIMENT; IN VIVO STUDY; NORMAL HUMAN; PHYSIOLOGY; PRIORITY JOURNAL; SIMULATION;

EID: 0141447810     PISSN: 09280987     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0928-0987(03)00200-8     Document Type: Article

References (24)

1. Backman J.T., Olkkola K.T., Aranko K., Himberg J.J., Neuvonen P.J. Dose of midazolam should be reduced during diltiazem and verapamil treatments. Br. J. Clin. Pharmacol. 37:1994;221-225.
2. Daneshmend T.K., Warnock D.W. Clinical pharmacokinetics of ketoconazole. Clin. Pharmacokinet. 14:1988;13-34.
3. Eberts F.S., Philopoulos B.S., Reineke L.M., Viek R.W. Triazolam disposition. Clin. Pharmacol. Ther. 29:1981;81-93.
4. Fang J., McKay G., Hubbard J.W., Hawes E.M., Midha K.K. Dose staggering as a strategy to reduce drug-drug interactions due to reversible enzyme inhibition between orally administered drugs with high first pass effect: a computer simulation study. Biopharm. Drug Dispos. 21:2000;249-259.
5. i values and impact of CYP3A5 expression. Drug Metab. Dispos. 27:1999;180-187.
6. Heykants J., Vanpeer A., Vandevelde V., Vanrooy P., Meuldermans W., Lavrijsen K., Woestenborghs R., Vancutsem J., Cauwenbergh G. The clinical pharmacokinetics of itraconazole - an overview. Mycoses. 32:1989;67-87.
7. Huang Y.C., Colaizzi J.L., Bierman R.H., Woestenborghs R., Heykants J. Pharmacokinetics and dose proportionality of ketoconazole in normal volunteers. Antimicrob. Agents. 30:1986;206-210.
8. Ishigam M., Uchiyama M., Kondo T., Iwabuchi H., Inoue S., Takasaki W., Ikeda T., Komai T., Ito K., Sugiyama Y. Inhibition of in vitro metabolism of simvastatin by itraconazole in humans and prediction of in vivo drug-drug interactions. Pharm. Res. 18:2001;622-631.
9. Jonsson G., Astrom A., Andersson P. Budesonide is metabolized by cytochrome P450 3A (CYP3A) enzymes in human liver. Drug Metab. Dispos. 23:1995;137-142.
10. Kanamitsu S., Ito K., Sugiyama Y. Quantitative prediction of in vivo drug-drug interactions from in vitro data based on physiological pharmacokinetics: use of maximum unbound concentration of inhibitor at the inlet to the liver. Pharm. Res. 17:2000;336-343.
11. Neuvonen P.J., Varhe A., Olkkola K.T. The effect of ingestion time interval on the ineraction between itraconazole and triazolam. Clin. Pharmacol. Ther. 60:1996;326-331.
12. Ryrfeldt A., Andersson P., Edsbacker S., Tonnesson M., Davies D., Pauwels R. Pharmacokinetics and metabolism of budesonide, a selective glucocorticoid. Eur. J. Resp. Dis. 63:1982;86-95.
13. Sawada T., Sako K., Yoshihara K., Nakamura K., Yokohama S., Hayashi M. Timed-release formulation to avoid drug-drug interaction between diltiazem and midazolam. J. Pharm. Sci. 92:2003;790-797.
14. Seidegard J. Reduction of the inhibitory effect of ketoconazole on budesonide pharmacokinetics by separation of their time of administration. Clin. Pharmacol. Ther. 68:2000;13-17.
15. Sheiner L.B., Beal S.L. Some suggestions for measuring predictive performance. J. Pharmacokin. Biopharm. 9:1981;503-512.
16. Thummel, K.E., Shen, D.D., 2001. Design and optimization of dosage regimens: pharmacokinetic data. In: Hardman, J.G., Limbird, L.E. (Eds.), Goodman & Gilman's The Pharmacological Basis of Therapeutics. McGraw-Hill, New York, pp. 1917-2024.
17. Tucker G.T., Houston J.B., Huang S.M. Optimizing drug development: strategies to assess drug metabolism/transporter interaction potential - towards a consensus. Brit. J. Clin. Pharmacol. 52:2001;107-117.
18. Varhe A., Olkkola K.T., Neuvonen P.J. Oral triazolam is potentially hazardous to patients receiving systemic antimycotics ketoconazole or itraconazole. Clin. Pharmacol. Ther. 56:1994;601-607.
19. vonMoltke L.L., Greenblatt D.J., Harmatz J.S., Duan S.X., Harrel L.M., Cotreau Bibbo M.M., Pritchard G.A., Wright C.E., Shader R.I. Triazolam biotransformation by human liver microsomes in vitro: effects of metabolic inhibitors and clinical confirmation of a predicted interaction with ketoconazole. J. Pharmacol. Exp. Ther. 276:1996;370-379.
20. Washington C.B., Flexner C., Sheiner L.B., Rosenkranz S.L., Segal Y., Aberg J.A., Blaschke T.F. Effect of simultaneous versus staggered dosing on pharmacokinetic interactions of protease inhibitors. Clin. Pharmacol. Ther. 73:2003;406-416.
21. Wilson, Z.E., Rostami-Hodjegan, A., Burn, J.L., Tooley, A., Boyle, J., Ellis, S.W., Tucker, G.T., 2003. Inter-individual variability in levels of human microsomal protein and hepatocellularity per gram of liver. Brit. J. Clin. Pharmacol., 56, in press.
22. Yamano K., Yamamoto K., Kotaki H., Sawada Y., Iga T. Quantitative prediction of metabolic inhibition of midazolam by itraconazole and ketoconazole in rats: implication of concentrative uptake of inhibitors into liver. Drug Metab. Dispos. 27:1999;395-402.
23. Yang J.S., Rostami-Hodjegan A., Tucker G.T. Prediction of ketoconazole interaction with midazolam. Brit. J. Clin. Pharmacol. 52:2001;472P-473P.
24. Yuan R., Flockhart D.A., Balian J.D. Pharmacokinetic and pharmacodynamic consequences of metabolism-based drug interactions with alprazolam, midazolam, and triazolam. J. Clin. Pharmacol. 39:1999;1109-1125.